Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens.
Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae
(ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus
(MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be
higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the
pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
Inclusion Criteria:
- • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton,
or Methodist Dallas Medical Centers between March 2018 and August 2021.
- >18 years old
Exclusion Criteria:
- • Outpatient visit
- Not admitted to an inpatient or observation status
Methodist Dallas Medical Center
Dallas, Texas, United States
Investigator: Matthew Crotty, PharmD
Contact: 214-941-2400
matthewcrotty@mhd.com
Investigator: Matthew Crotty, PharmD
Crystee Cooper, DHEd
214-947-1280
clinicalresearch@mhd.com
Zaid Haddadin, MS
214-947-1280
clinicalresearch@mhd.com
Mathew Crotty, PharmD, Principal Investigator
Methodist Dallas Medical Center